AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners
November 6, 2024 5:58 AM ESTLeerink Partners analyst David Risinger lowered the price target on AnaptysBio (NASDAQ: ANAB) to $45.00 (from $47.00) while maintaining a Outperform rating.
The analyst comments " Bottom Line: ANAB reported 3Q results and stated that there have been no blinded safety issues to date with either its BTLA... More
AnaptysBio, Inc. (ANAB) Tops Q3 EPS by 56c
November 5, 2024 4:58 PM ESTAnaptysBio, Inc. (NASDAQ: ANAB) reported Q3 EPS of ($1.14), $0.56 better than the analyst estimate of ($1.70). Revenue for the quarter came in at $30.02 million versus the consensus estimate of $6.92 million.
For earnings history and earnings-related data on AnaptysBio, Inc. (ANAB) click here.
... MoreAnaptysbio (ANAB) Files $500M Mixed Shelf
November 5, 2024 4:30 PM ESTAnaptysbio (NASDAQ: ANAB) has filed $500,000,000 mixed shelf of:
Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units
